SCCM is performing maintenance on its websites. For the best browsing experience, please use Microsoft Edge or Safari. Those using Chrome or Firefox may experience access issues at this time.

Discovery VIRUS COVID-19 Registry

A global COVID-19 registry that tracks ICU and hospital care patterns in near real time

visual bubble
visual bubble
visual bubble
visual bubble

Viral Infection and Respiratory Illness Universal Study (VIRUS) is a prospective, cross-sectional, observational study and registry of all eligible adult and pediatric patients who are admitted to a hospital. There is no intervention or patient interaction. Only de-identified data are used for analysis.

ClinicalTrials.gov Identifier: NCT04323787

VIRUS COVID-19 Registry Dashboard

 

SCCM




 
                  

VIRUS COVID-19 Registry Enrollment

Please check whether your site is already enrolled as a VIRUS participating site before enrolling. Then complete the intake form and download the frequently asked questions.

Check the VIRUS Participation List
Complete the Intake Form to Participate
Download VIRUS FAQs
 

Inclusion Criteria

  • COVID-19 PCR (or other SARS-CoV-2) test positive within 21 days
  • COVID-19 PCR pending
  • COVID-19 high clinical suspicion

Primary Aims

  • Create a real-time COVID-19 registry of current ICU and hospital care patterns to allow evaluation of safety and observational effectiveness of COVID-19 practices
  • Determine practice variations across hospitals

Hypotheses

The registry will be essential for near-real-time observational comparative effectiveness studies to determine effective treatment strategies and/or provide meaningful hypotheses for clinical trials.


Institutional Review Board: Waiver of Consent

A waiver of informed consent for data collection is being requested for this study from participating sites. No patients will be contacted, but clinicians participating in the study will be surveyed for feedback and satisfaction. For any questions, contact Vishakha Kumar.
 

Join the SCCM Connect Discovery Group

Approved sites with IRB approval can join the SCCM Connect Discovery Group. Access includes a discussion board and the ability to connect with other Discovery participants.

This is the best way to get regular updates about VIRUS!

Request to join the Discovery SCCM Connect Group
 

STOP-VIRUS ICU Learning Collaborative

ICUs participating in the VIRUS Registry may also be among the 20 sites participating in the STOP-VIRUS collaborative. For more information about this network of ICUs, its leaders and participants, and the learning material being developed, click here.


Recent Publications

Gastrointestinal Manifestations in Hospitalized Children With Acute SARS-CoV-2 Infection and Multisystem Inflammatory Condition: An Analysis of the VIRUS COVID-19 Registry
Sayed IA, Bhalala U, Strom L, et al; VIRUS Investigators. Pediatr Infect Dis J. 2022 Sep 1;41(9):751-758. doi:10.1097/INF.0000000000003589.
Program Type: VIRUS DISCOVERY

Variation in Use of High-Flow Nasal Cannula and Noninvasive Ventilation Among Patients With COVID-19
Garcia MA, Johnson SW, Sisson EK, et al; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Respir Care. 2022 Aug;67(8):929-938. doi:10.4187/respcare.09672.
Program Type: VIRUS DISCOVERY

Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19
Gupta N, Settle L, Brown BR, et al; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Crit Care Med. 2022 Jul 27. 10.1097/CCM.0000000000005627. Online ahead of print.
Program Type: VIRUS DISCOVERY

Early Combination Therapy With Immunoglobulin and Steroids Is Associated With Shorter ICU Length of Stay in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With COVID19: A Retrospective Cohort Analysis From 28 U.S Hospitals
Harthan AA, Nadiger M, McGarvey JS, et al; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Pharmacotherapy. 2022 Jul;42(7):529-539. doi:10.1002/phar.2709.
Program Type: VIRUS DISCOVERY

Admission Code Status and End-of-Life Care for Hospitalized Patients With COVID-19
Kiker WA, Cheng S, Pollack LR, et al; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group.  J Pain Symptom Manage. 2022 Jun 25;S0885-3924(22)00788-6. doi:10.1016/j.jpainsymman.2022.06.014.
Program Type: VIRUS DISCOVERY

visual bubble
visual bubble
visual bubble
visual bubble
visual bubble

VIRUS Investigators 

Discovery, the Critical Care Research Network, is leading the efforts for this global COVID-19 registry. 
Rahul Kashyap, MBA, MD
VIRUS Principal Investigator
Rahul Kashyap, MBA, MD

Mayo Clinic
Rochester, Minnesota, USA

Allan J. Walkey, MD, MSc
VIRUS Co-Principal Investigator
Allan J. Walkey, MD, MSc

Boston University
Boston, Massachusettes, USA

Juan Pablo Domecq Garces, MD
VIRUS Co-Principal Investigator
Juan Pablo Domecq Garces, MD

Mayo Clinic Foundation
Rochester, Minnesota, USA

Vishakha Kumar, MD, MBA
VIRUS Co-Principal Investigator
Vishakha Kumar, MD, MBA

Discovery, the Critical Care Research Network
Society of Critical Care Medicine


VIRUS Ancillary Studies

Ancillary Proposal Review Process

Submission process: Ancillary study proposals may be submitted for a subset of de-identified data for research purposes by investigators of participating sites in the VIRUS study. Proposals are submitted via an online submission portal. Submitted proposals are reviewed by the Discovery VIRUS Publication Review Workgroup for approval and feedback.

Datasets may be made available to outside groups (nonparticipating sites and investigators) after initial publication of the data by study principal investigators within 12 months of study conclusion. A Data Use Agreement must be in place for this type of request.

Review Process: The Discovery VIRUS Publication Review Workgroup will assign two to three reviewers per proposal. The timeline for approval is up to 30 days.

The proposal submission portal is now open. Access the submission portal.

 

Information for Investigators

  1. Any conflict of interest with the ancillary study proposal must be disclosed by reviewers and investigators.
  2. Ancillary study proposals are kept blinded from the VIRUS core investigator group.
  3. SCCM, including the VIRUS core investigators group, has first right of publication on the dataset for research hypotheses outlined for the VIRUS Study.
  4. Study participants can serve on the writing group with the VIRUS core investigators team if their ancillary study ideas overlap or align with the VIRUS overall project aims.
  5. National and international collaboration on ancillary proposal submission is encouraged.
  6. Ancillary proposal approval and data sharing depends on data quality and completion of the investigator’s own site data for the VIRUS study.

Ancillary Study Approval Process

Manuscript Approval Process

Ancillary Study Approval Process

Feedback on proposals will be shared with investigators. The Discovery VIRUS Publication Review Workgroup makes rapid review of proposals a priority. Once approved, investigators receive access to the de-identified subset of data from the VIRUS dataset.